SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.

News Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Equities

6990

CNE1000062J1

Market Closed - Hong Kong S.E. Other stock markets 04:08:22 2024-05-10 am EDT			5-day change	1st Jan Change
189 ^HKD	+6.48%		+12.63%	+83.67%

May. 08	Sichuan Kelun-biotech Biopharmaceutical to Place 3.6 Million Shares; Inks Subscription Deal for 4.4 Million Shares	MT
May. 06	Kelun-Biotech's Lung Cancer Drug Advances to Phase 2 Trials in US; Shares Up 8%	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sichuan Kelun-biotech Biopharmaceutical to Place 3.6 Million Shares; Inks Subscription Deal for 4.4 Million Shares	May. 07	MT
Kelun-Biotech's Lung Cancer Drug Advances to Phase 2 Trials in US; Shares Up 8%	May. 06	MT
Sichuan Kelun-Biotech Buys Structured Deposits Worth 680 Million Yuan	Apr. 15	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Study Results for Core Product Scituzumab Turumotecan (SAC-TMT) at AACR Annual Meeting 2024	Apr. 07	CI
Kelun-Biotech Shrinks Loss by 7% in 2023	Mar. 26	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
China Healthcare Stocks Rally on Hopes for Government Support	Mar. 14	DJ
China Grants Breakthrough Therapy Designation for Kelun-Biotech's Breast Cancer Treatment	Mar. 13	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Its Core Product SKB264 (MK-2870) Granted Breakthrough Therapy Designation for First-Line Treatment of Unresectable Locally Advanced, Recurring or Metastatic Pd-L1 Negative Tnbc by the National Medical Products Administration	Mar. 13	CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Key Product A400 Granted Fast Track Designation by the US Food and Drug Administration	Mar. 11	CI
Kelun-Biotech Shares Start Trading in Shanghai's Southbound Stock Connect	Mar. 04	MT
Kelun-Biotech Licensee Starts Phase 3 Trials for Cancer Treatment; Shares Rise 5%	Feb. 23	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Collaboration with Merck Sharp & Dohme LLC	Feb. 22	CI
Kelun-Biotech Chosen as Constituent Stock of Hang Seng Indexes; Shares Fall 3%	Feb. 18	MT
Kelun-Biotech Controlling Shareholder Ups Stake; Shares Rise 4%	Jan. 22	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.(SEHK:6990) added to S&P Global BMI Index	Dec. 18	CI
China Accepts Kelun-Biotech's Application for Triple-Negative Breast Cancer Treatment; Shares Fall 4%	Dec. 11	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces New Drug Application for Core Product SKB264 (MK-2870) Accepts by the National Medical Products Administration	Dec. 10	CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to Present the Updated Efficacy and Safety Results from Core Product	Nov. 30	CI
US FDA Grants Orphan Drug Designation for Kelun-Biotech's Solid Tumor Drug	Nov. 26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Equities

6990

CNE1000062J1

Summary

Filters